公开(公告)号：US5403308A

公开(公告)日：1995-04-04

申请号：US980980

申请日：1992-11-24

申请人： Leroy Wood ,  Donn Boyle ,  William R. Potter

发明人： Leroy Wood ,  Donn Boyle ,  William R. Potter

IPC分类号： A61B5/00 ,  A61B18/22 ,  A61N5/06 ,  G02B6/32 ,  G02B6/36 ,  G02B6/42 ,  G02B23/22 ,  G02B23/24 ,  G02B23/26

CPC分类号： A61B5/0059 ,  A61N5/0601 ,  A61N5/062 ,  G02B23/22 ,  G02B23/2423 ,  G02B23/26 ,  G02B6/32 ,  G02B6/4203 ,  A61B2018/2261 ,  G02B6/325 ,  G02B6/3644

摘要： A submersible lens fiberoptic assembly for PDT treatment includes an optical fiber, a fiber jacket, a ball lens made of zirconia and a housing. This fiberoptic assembly is simple and inexpensive to manufacture, and has a high quality of output light beam. A submersible lens fiberoptic assembly for PDT treatments is also disclosed which uses a hemisphere ball lens for treatment of areas inaccessible to a normal "forward looking" lens.

摘要翻译： 用于PDT处理的潜水透镜光纤组件包括光纤，纤维夹套，由氧化锆制成的球透镜和壳体。 该光纤组件制造简单且便宜，并且具有高质量的输出光束。 还公开了一种用于PDT处理的潜水透镜光纤组件，其使用半球球透镜来处理正常“前视”透镜不能接近的区域。

公开(公告)号：US5190536A

公开(公告)日：1993-03-02

申请号：US839724

申请日：1992-02-19

申请人： Leroy Wood ,  Donn Boyle ,  William R. Potter

发明人： Leroy Wood ,  Donn Boyle ,  William R. Potter

IPC分类号： A61B5/00 ,  A61B18/22 ,  A61N5/06 ,  G02B6/32 ,  G02B6/36 ,  G02B6/42 ,  G02B23/22 ,  G02B23/24 ,  G02B23/26

CPC分类号： A61B5/0059 ,  A61N5/0601 ,  A61N5/062 ,  G02B23/22 ,  G02B23/2423 ,  G02B23/26 ,  G02B6/32 ,  G02B6/4203 ,  A61B2018/2261 ,  G02B6/325 ,  G02B6/3644

摘要： A submersible lens fiberoptic assembly for PDT treatment includes an optical fiber, a fiber jacket, a ball lens made of zirconia and a housing. This fiberoptic assembly is simple and inexpensive to manufacture, and has a high quality of output light beam. A submersible lens fiberoptic assembly for PDT treatments is also disclosed which uses a hemisphere ball lens for treatment of areas inaccessible to a normal "forward looking" lens.

摘要翻译： 用于PDT处理的潜水透镜光纤组件包括光纤，纤维夹套，由氧化锆制成的球透镜和壳体。 该光纤组件制造简单且便宜，并且具有高质量的输出光束。 还公开了一种用于PDT处理的潜水透镜光纤组件，其使用半球球透镜来处理正常“前视”透镜不能接近的区域。

公开(公告)号：US5671317A

公开(公告)日：1997-09-23

申请号：US680936

申请日：1996-07-16

申请人： Kenneth R. Weishaupt ,  William R. Potter ,  Leroy Wood

发明人： Kenneth R. Weishaupt ,  William R. Potter ,  Leroy Wood

IPC分类号： A61N5/00 ,  A61N5/06 ,  A61N5/067 ,  G02B6/46

CPC分类号： A61N5/0616 ,  A61N2005/0633 ,  A61N2005/0644 ,  A61N2005/067 ,  A61N5/062

摘要： Method and apparatus for stabilizing a fiber optic relative to the skin surface of a patient so that radiation from the fiber optic strikes a defined surface area on the skin independently of patient movement. The apparatus comprises a polypod support having a fiber optic supporting platform and at least three legs to form a tripod. Each of the legs has two ends, a first of which is secured to the fiber optic supporting platform and the second of which is securely attached to the skin of the patient, either directly or by means of a foot attached to the second end. The method of the present invention comprises attaching a polypod, as above described, to the skin of a patient and irradiating a defined surface area by means of an end of a fiber optic held by the polypod support.

摘要翻译： 用于使光纤相对于患者皮肤表面稳定的方法和装置，使得来自光纤的辐射独立于患者运动而撞击皮肤上限定的表面区域。 该装置包括具有光纤支撑平台和至少三条腿以形成三脚架的息肉支架。 每个腿部具有两个端部，第一个端部固定到光纤支撑平台上，其中第二个端部直接地或通过连接到第二端部的脚牢固地附接到患者的皮肤。 本发明的方法包括如上所述将息肉附着到患者​​的皮肤上，并通过由息肉支撑体保持的光纤的一端照射限定的表面区域。

公开(公告)号：US06868221B1

公开(公告)日：2005-03-15

申请号：US10434420

申请日：2003-05-08

申请人： Leroy M. Wood ,  William R. Potter ,  Kenneth R. Weishaupt

发明人： Leroy M. Wood ,  William R. Potter ,  Kenneth R. Weishaupt

IPC分类号： A61B19/00 ,  A61N5/06 ,  G02B6/46

CPC分类号： A61B90/11 ,  A61B90/50 ,  A61N5/062

摘要： The present invention relates to an apparatus which includes a polypod support which includes a fiber optic supporting platform. The fiber optic supporting platform includes an opening. The apparatus further includes at least three legs forming a tripod, each of the legs having two ends, a first end being secured to the fiber optic supporting platform and the second end being adapted for attachment to the skin of the patient, a first tube having an outer diameter, a second tube having an outer diameter and an inner diameter, where the inner diameter of the second tube surrounds the outer diameter of the first tube and where the outer diameter of the second tube is slidably mounted within the opening of the fiber optic surrounding platform and a fiber optic.

摘要翻译： 本发明涉及一种装置，其包括一个包含光纤支撑平台的息肉支架。 光纤支撑平台包括开口。 所述装置还包括形成三脚架的至少三个腿部，所述腿部中的每一个具有两个端部，第一端部固定到所述光纤支撑平台，并且所述第二端部适于附接到所述患者的皮肤，所述第一管具有 外径，第二管具有外径和内径，第二管的内径围绕第一管的外径，第二管的外径可滑动地安装在纤维的开口内 光学周边平台和光纤。

公开(公告)号：US5205291A

公开(公告)日：1993-04-27

申请号：US772235

申请日：1991-10-07

申请人： William R. Potter

发明人： William R. Potter

IPC分类号： A61B5/00 ,  A61N5/06

CPC分类号： A61N5/062 ,  A61B5/0059 ,  A61B5/415 ,  A61B5/418 ,  A61N5/0601

摘要： A method and apparatus for in vivo detection of abnormal tissue in patients by irradiating a diagnostic region simultaneously with at least two wavelengths of incident light, and detecting the resulting fluorescence of normal and abnormal tissue. The patient is provided with a photosensitizer which preferentially collects in abnormal tissue, and beams of light--preferably at about 612 and 632.8 nm--are directed to the diagnostic region. The beams of light are chopped at 90 and 135 Hz, respectively. Fluorescent light from the diagnostic region is then detected, and an electronic signal is generated relating to the intensity of the fluorescence. Because of the chopping of the incident beams, the fluorescent light and the resulting electronic signal are also chopped. The electronic signal is provided as input to phase-locked amplifier circuitry, which differentiates between the contribution to the signal resulting from each of the 612 and 632.8 nm incident beams. A difference signal is provided as output to headphones, and the operator of the apparatus is notified of presence of abnormal tissue by changes in pitch of the difference signal. The source for the light may be lasers or an arc lamp, and there may be three or more incident wavelengths used.

摘要翻译： 一种用于通过与至少两个入射光波长同时照射诊断区域并检测所产生的正常和异常组织的荧光来体内检测患者异常组织的方法和装置。 患者设置有优先收集在异常组织中的光敏剂，并且优选约612和632.8nm的光束被引导到诊断区域。 光束分别以90和135 Hz切割。 然后检测来自诊断区域的荧光，并产生与荧光强度有关的电子信号。 由于入射光束的斩波，荧光灯和所产生的电子信号也被切碎。 电子信号作为输入提供给锁相放大器电路，其区分对由612和632.8nm入射光束中的每一个产生的信号的贡献。 提供差分信号作为耳机的输出，并且通过差异信号的音调的变化来通知设备的操作者异常组织的存在。 光源可以是激光器或弧光灯，并且可以存在三个或更多个入射波长。

公开(公告)号：US5028621A

公开(公告)日：1991-07-02

申请号：US352774

申请日：1989-05-16

申请人： Thomas J. Dougherty ,  William R. Potter ,  Kenneth R. Weishaupt

发明人： Thomas J. Dougherty ,  William R. Potter ,  Kenneth R. Weishaupt

IPC分类号： A61B5/00 ,  A61K31/40 ,  A61K41/00 ,  A61K49/00 ,  A61K51/00 ,  A61N5/06 ,  A61P35/00 ,  A61P43/00 ,  C07D487/22 ,  C07D519/00 ,  C09B47/00 ,  G02B6/04 ,  G02B6/26 ,  G02B6/42

CPC分类号： A61K31/40 ,  A61B5/411 ,  A61B5/416 ,  A61K41/0071 ,  A61N5/0601 ,  A61N5/062 ,  C07D519/00 ,  G02B6/262 ,  G02B6/4204 ,  A61B5/0071 ,  A61B5/0084 ,  G02B6/4298 ,  Y10S607/901

摘要： To obtain tumor-selective, photosensitizing drugs useful in the localization of neoplastic tissue and treatment of abnormal neoplastic tissue such as tumors, one of two methods is used. In the first method, a hydrolyzed mixture of the products of reaction of hematoporphyrin with acetic acid and sulfuric acid is cycled through a microporous membrane system to exclude low molecular weight products. In the second method, drugs are synthesized or derived from other pyrrole compounds. The drugs (1) include two covalently bound groups, each with four rings, some of which are pyrroles such as phlorins, porphyrins, chlorins, substituted pyrroles, substituted chlorins or substituted phlorins, each group being arranged in a ring structure, connected covalently to another group and have a triplet energy state above 37.5 kilocalories per mole; (2) are soluble in water, forming an aggregate of over 10,000 molecular weight in water and have an affinity for each other compared to serum protein such that 10 to 100 percent remain self aggregated in serum protein; and (3) are lipophyllic and able to disaggregate and attach to cell plasma, nuclear membrane, mitochondria, lysosomes and tissue. The drug obtained by the first method has an empirical formula of approximately C.sub.68 H.sub.70 N.sub.8 O.sub.11 or C.sub.68 H.sub.66 N.sub.8 O.sub.11 Na.sub.4. Neoplastic tissue retains the drug after it has cleared normal tissues and illumination results in necrosis. Moreover, other photosensitizing materials may be combined with a carrier that enters undesirable tissues and cells of the reticular endothelial system such as macrophages. These photosensitizing materials: (1) must have a triplet energy state above 3.5 kilocalories per mole; (2) cannot be easily oxidized; and (3) not physically quench any required energy state. Preferably, this photosensitizing material should be lipophlic.

摘要翻译： 为了获得肿瘤选择性的光敏药物，可用于肿瘤组织的定位和治疗异常肿瘤组织如肿瘤，使用两种方法之一。 在第一种方法中，血卟啉与乙酸和硫酸的反应产物的水解混合物循环通过微孔膜系统以排除低分子量产物。 在第二种方法中，合成或衍生自其他吡咯化合物的药物。 药物（1）包括两个共价结合的基团，每个具有四个环，其中一些是吡咯，例如卟啉，卟啉，二氢卟酚，取代的吡咯，取代的二氢卟酚或取代的藜芦烯，每个组排列成环结构，共价连接到 另一组，三重态能量每摩尔高于37.5千卡; （2）可溶于水，与血清蛋白质相比，在水中形成了超过10,000分子量的聚集体，并且与血清蛋白质具有亲和力，使得10％至100％在血清蛋白中保持自我聚集; 和（3）是脂蛋白的并且能够解聚并附着于细胞血浆，核膜，线粒体，溶酶体和组织。 通过第一种方法获得的药物具有约C68H70N8O11或C68H66N8O11Na4的经验式。 肿瘤组织清除正常组织后保留药物，照明会导致坏死。 此外，其它光敏材料可以与进入网状内皮系统的不希望的组织和细胞如巨噬细胞的载体组合。 这些光敏材料：（1）必须具有每千克3.5千卡以上的三线态能量状态; （2）不易氧化; 和（3）不能物理地淬灭任何所需的能量状态。 优选地，该光敏材料应该是脂肪族的。

公开(公告)号：US4649151A

公开(公告)日：1987-03-10

申请号：US609991

申请日：1984-05-14

申请人： Thomas J. Dougherty ,  William R. Potter ,  Kenneth R. Weishaupt

发明人： Thomas J. Dougherty ,  William R. Potter ,  Kenneth R. Weishaupt

IPC分类号： A61B5/00 ,  A61K31/40 ,  A61K41/00 ,  A61K49/00 ,  A61K51/00 ,  A61N5/06 ,  A61P35/00 ,  A61P43/00 ,  C07D487/22 ,  C07D519/00 ,  C09B47/00 ,  G02B6/04 ,  G02B6/26 ,  G02B6/42

CPC分类号： A61K31/40 ,  A61B5/411 ,  A61B5/416 ,  A61K41/0071 ,  A61N5/0601 ,  A61N5/062 ,  C07D519/00 ,  G02B6/262 ,  G02B6/4204 ,  A61B5/0071 ,  A61B5/0084 ,  G02B6/4298 ,  Y10S607/901

摘要： To obtain tumor-selective, photosensitizing drugs useful in the localization of neoplastic tissue and treatment of abnormal neoplastic tissue such as tumors, one of two methods is used. In the first method, a hydrolyzed mixture of the products of reaction of hematoporphyrin with acetic acid and sulfuric acid is cycled through a microporous membrane system to exclude low molecular weight products. In the second method, drugs are synthesized or derived from other pyrrole compounds. The drugs: (1) include two covalently bound groups, each with four rings, some of which are pyrroles such as phlorins, porphyrins, chlorins, substituted pyrroles, substituted chlorins or substituted phlorins, each group being arranged in a ring structure, connected covalently to another group and have a triplet energy state above 37.5 kilocalories per mole; (2) are soluble in water, forming an aggregate of over 10,000 molecular weight in water and have an affinity for each other compared to serum protein such that 10 to 100 percent remain self aggregated in serum protein; and (3) are lipophyllic and able to disaggregate and attach to cell plasma, nuclear membrane, mitochondria, lysosomes and tissue. The drug obtained by the first method has an empirical formula of approximately C.sub.68 H.sub.70 N.sub.8 O.sub.11 or C.sub.68 H.sub.66 N.sub.8 O.sub.11 Na.sub.4.

摘要翻译： 为了获得肿瘤选择性的光敏药物，可用于肿瘤组织的定位和治疗异常肿瘤组织如肿瘤，使用两种方法之一。 在第一种方法中，血卟啉与乙酸和硫酸的反应产物的水解混合物循环通过微孔膜系统以排除低分子量产物。 在第二种方法中，合成或衍生自其他吡咯化合物的药物。 药物：（1）包括两个共价结合的基团，每个具有四个环，其中一些是吡咯，例如卟啉，卟啉，二氢卟酚，取代的吡咯，取代的二氢卟酚或取代的藜芦烯，每个组排列成环结构，共价连接 到另一组，并具有高于每摩尔37.5千卡的三线态能量状态; （2）可溶于水，与血清蛋白质相比，在水中形成了超过10,000分子量的聚集体，并且与血清蛋白质具有亲和力，使得10％至100％在血清蛋白中保持自我聚集; 和（3）是脂蛋白的并且能够解聚并附着于细胞血浆，核膜，线粒体，溶酶体和组织。 通过第一种方法获得的药物具有约C68H70N8O11或C68H66N8O11Na4的经验式。

公开(公告)号：US6103751A

公开(公告)日：2000-08-15

申请号：US102417

申请日：1998-06-22

申请人： Ravindra K. Pandey ,  William R. Potter ,  Thomas J. Dougherty

发明人： Ravindra K. Pandey ,  William R. Potter ,  Thomas J. Dougherty

IPC分类号： A61K49/00 ,  C07D487/22 ,  C07D519/00 ,  A61K31/40

CPC分类号： A61K49/0036 ,  A61K49/0052 ,  C07D487/22 ,  C07D519/00

摘要： A carotene conjugate of the formula: ##STR1## where R.sup.1 is hydrogen or methyl; R.sup.2 is: ##STR2## R.sup.3, R.sup.4 and R.sup.5 are independently, hydrogen, methyl or ethyl; R.sup.6 and R.sup.7 are independently --R.sup.13, --OR , --C(R.sup.6)(O), --C(R.sup.16).sub.2 OR.sup.13, --CH.dbd.CHR.sup.13, or --(CH.sub.2)R.sup.14 ; R.sup.8 is --R.sup.13, --OR.sup.13, --C(R.sup.16)(O), --C(R.sup.16).sub.2 OR.sup.13, --CH.dbd.CHR.sup.13, or --(CH.sub.2)R.sup.14 or taken with R.sup.10 is .dbd.O; R.sup.9 is --R.sup.13, --OR.sup.13, --C(R.sup.16)(O), --C(R.sup.16).sub.2 OR.sup.13, --CH.dbd.CHR.sup.13, or --(CH.sub.2)R.sup.14 or taken with R.sup.10 is a chemical bond; R.sup.10 is --R.sup.13, --OR.sup.13, --C(R.sup.16)(O) , --C(R.sup.16).sub.2 OR.sup.13, --CH.dbd.CHR.sup.13, or --(CH.sub.2)R.sup.14 or taken together with R.sup.9 is a chemical bond or taken with R.sup.8 is .dbd.O; R.sup.11 is R.sup.13, or --OR.sup.13 ; R.sup.12 is --C(R.sup.13).sub.2 C(Y)--, --C(O)O(O)C--, --C(NR.sup.13)O(O)C--, or --C(O)N(R.sup.15)--C(O)--; R.sup.13 is, independently at each occurrence, hydrogen or lower alkyl of from 1 through about 10 carbon atoms; R.sup.14 is an amino acid residue, R.sup.15 is --R.sup.13, --R.sup.14, or --C(O)NHR.sup.13 ; R.sup.16 is, independently at each occurrence, hydrogen or lower alkyl of 1 to about 4 carbon atoms and Y is .dbd.O, .dbd.S, or 2H--.

摘要翻译： 下式的胡萝卜素缀合物：其中R1是氢或甲基; R2是：R3，R4和R5独立地是氢，甲基或乙基; R6和R7独立地是-R13，-OR，-C（R6）（O），-C（R16）2OR13，-CH = CHR13或 - （CH2）R14; R8是-R13，-OR13，-C（R16）（O），-C（R16）2OR13，-CH = CHR13或 - （CH2）R14，或R10为= R9为-R13，-OR13，-C（R16）（O），-C（R16）2OR13，-CH = CHR13或 - （CH2）R14或R10为化学键; R 10为-R 13，-OR 13，-C（R 16）（O），-C（R 16）2 OR 13，-CH = CHR 13或 - （CH 2）R 14或与R 9一起为化学键， O; R11是R13或-OR13; R 12是-C（R 13）2 C（Y） - ， - C（O）O（O）C - ， - C（NR 13）O（O）C-或-C（O）N（R 15） O） - ; R 13在每次出现时独立地为氢或1至约10个碳原子的低级烷基; R14是氨基酸残基，R15是-R13，-R14或-C（O）NHR13; R 16在每次出现时独立地为氢或1至约4个碳原子的低级烷基，Y为= O，= S或2H-。

公开(公告)号：US5219345A

公开(公告)日：1993-06-15

申请号：US502183

申请日：1990-03-30

申请人： William R. Potter

发明人： William R. Potter

IPC分类号： A61B1/00 ,  A61B5/00

CPC分类号： A61B5/0071 ,  A61B1/00165 ,  A61B5/0084

摘要： A system for monitoring the condition of the distal tip of an optical treatment fiber, including a monitor for measuring the intensity of light backscattered from the distal tip. A treatment laser is coupled to a jumper fiber, which has its distal end optically coupled to the proximal end of the treatment fiber, for transmitting light from the laser to treatment tissue at a treatment site in a patient. The monitor determines the amount of laser light backscattered from the distal tip of the treatment fiber, thereby indicating whether an abnormal condition exists at the distal tip. At least one additional fiber is optically coupled to the treatment fiber for receiving tip backscatter unpolluted by interface backscatter between the jumper fiber and the treatment fiber. Additional fibers may also be optically coupled to the treatment fiber for receiving and monitoring the tip backscatter light or return light from the treatment tissue.

摘要翻译： 一种用于监测光学处理光纤的远端的状态的系统，包括用于测量从远端向后散射的光的强度的监视器。 治疗激光器耦合到跨接光纤，其具有光学耦合到处理光纤的近端的远端，用于将光从激光器传输到患者治疗部位的治疗组织。 监视器确定从治疗纤维的远端向后扩散的激光的量，从而指示远端处是否存在异常状况。 至少一个额外的纤维光学耦合到处理纤维，用于接收未被穿过跳线纤维和处理纤维之间的界面反向散射而被污染的末端反向散射。 另外的纤维还可以光学耦合到处理纤维，用于接收和监测尖端反向散射光或从处理组织返回光。

公开(公告)号：US5111821A

公开(公告)日：1992-05-12

申请号：US268723

申请日：1988-11-08

申请人： William R. Potter

发明人： William R. Potter

IPC分类号： A61B5/00 ,  A61N5/06

CPC分类号： A61B5/0059 ,  A61B5/415 ,  A61B5/418 ,  A61N5/0601 ,  A61N5/062

摘要： A method and apparatus for in vivo detection of abnormal tissue in patients by irradiating a diagnostic region simultaneously with at least two wavelengths of incident light, and detecting the resulting fluorescence of normal and abnormal tissue. The patient is provided with a photosensitizer which preferentially collects in abnormal tissue, and beams of light--preferably at about 612 and 632.8 nm--are directed to the diagnostic region. The beams of light are chopped at 90 and 135 Hz, respectively. Fluorescent light from the diagnostic region is then detected, and an electronic signal is generated relating to the intensity of the fluorescence. Because of the chopping of the incident beams, the fluorescent light and the resulting electronic signal are also chopped. The electronic signal is provided as input to phase-locked amplifier circuitry, which differentiates between the contribution to the signal resulting from each of the 612 and 632.8 nm incident beams. A difference signal is provided as output to headphones, and the operator of the apparatus is notified of presence of abnormal tissue by changes in pitch of the difference signal. The source for the light may be lasers or an arc lamp, and there may be three or more incident wavelengths used.

摘要翻译： 一种用于通过与至少两个入射光波长同时照射诊断区域并检测所产生的正常和异常组织的荧光来体内检测患者异常组织的方法和装置。 患者设置有优先收集在异常组织中的光敏剂，并且优选约612和632.8nm的光束被引导到诊断区域。 光束分别以90和135 Hz切割。 然后检测来自诊断区域的荧光，并产生与荧光强度有关的电子信号。 由于入射光束的斩波，荧光灯和所产生的电子信号也被切碎。 电子信号作为输入提供给锁相放大器电路，其区分对由612和632.8nm入射光束中的每一个产生的信号的贡献。 提供差分信号作为耳机的输出，并且通过差异信号的音调的变化来通知设备的操作者异常组织的存在。 光源可以是激光器或弧光灯，并且可以存在三个或更多个入射波长。